NCT07310186Not yet recruiting
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy: A Multi-center, Retro- and Prospective, Observational, Real-World Study
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled "Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy", aiming to obtain real-world data from the Chinese population.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 22 Jul 2025
- Start date
- 30 Dec 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07310186
What you commit to
- Study type: Observational
- Planned participants: 200
- From 30 Dec 2025 to the primary completion date, 30 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have not received pola-based regimen treatment.
Other
- Incomplete electronic medical records or unreachable by telephone.
Who the study is looking for
- Patients diagnosed with DLBCL
- Age ≥18 years
- Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy.
- Availability of complete electronic medical records and ability to be contacted via telephone.
- Full understanding of the study, voluntary participation, and willingness to sign the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.